Anuh Pharma (506260) Q2 2026 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended 30th September 2025, along with revised governance policies and bonus share issuance in July 2025.

• Financial results reviewed by the Audit Committee and subjected to limited review by statutory auditors.

Financial highlights

• Revenue from operations for Q2 FY26 was ₹18,588.27 lakhs, up from ₹16,595.38 lakhs in Q2 FY25.

• Net profit after tax for Q2 FY26 stood at ₹761.25 lakhs, compared to ₹1,365.34 lakhs in Q2 FY25.

• EBITDA for Q2 FY26 was ₹1,285.81 lakhs with an EBITDA margin of 6.92%.

• Basic and diluted EPS for Q2 FY26 were ₹0.76, reflecting the effect of the 1:1 bonus share issue.

Outlook and guidance

• Revised policies on code of conduct, document preservation, insider trading, and CSR adopted to align with regulatory updates and best practices.